Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

Fig. 5

Mutations in ALK downstream signaling cause ALK inhibitor resistance in ALK-mutated neuroblastomaa Clinical covariates of the high-risk neuroblastoma cohort (n = 4) before and after development of ALK inhibitor resistance. b Magnetic resonance imaging (MRI) scans and Iodine-123 metaiodobenzylguanidine scintigraphy scans (MIBG) of patients whose tumors harbored ALKR1275Q or ALKF1174L mutations during treatment with ceritinib. After partial remission both, patient 1 and 2, relapsed under ceritinib treatment and de novo NF1 mutations were detected using targeted sequencing. Tumor lesions are highlighted by red circles. c MIBG- scans of patient whose tumor harbored ALKR1275Q mutations during treatment with ceritinib and lorlatinib. After partial remission the patient relapsed under ALKi treatment and de novo NRAS mutations were detected using targeted sequencing. Tumor lesions are highlighted by red circles

Back to article page

Molecular Cancer

ISSN: 1476-4598